## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT APPLICATION

Inventor(s):	Alexander J. Somogyi						
Appl. No.:	10/788,802	Art Unit:	2195				
Confirm. No.:	7862	Examiner:	Camquy Troung				
Filed:	February 27, 2004		-				
Title:	PROTECTION AGAINST INTERLEAVING	Customer No. 80548					
	TRANSACTIONS USING A						
	TRANSACTION MANAGER						
	I hereby certify that this correspondence is being electronically of facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.  (Attorney Signature)						
Thomas K. Plunkett, Reg. No. 57,253 Signature Date: February 4, 2009							
TRANSMITTAL LETTER RE INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.56							
Mail Stop Amer							
Commissioner for Patents							

Sir:

P.O. Box 1450 Alexandria, VA 22313-1450

In re Application

It is requested that the information identified in this statement be considered by the Examiner and made of record in the above-identified application. This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56. If this is a continuation, divisional or continuation-in-part application, it is understood that the Examiner will consider all information which was considered by the Office in a parent application. MPEP §609. Such information therefore is not listed herein unless it is desired that the information be printed on a patent issuing from the subject application.

## Enclosed with this statement are the following:

- Form PTO-1449. The Examiner is requested to initial the form and return it to the undersigned in accordance with M.P.E.P. 8609.
- ✓ As allowed under 37 C.F.R § 1.98(a)(2)(ii), no copies of the U.S. patents and U.S. patent application publications are enclosed, unless required by the office.
- ✓ As allowed under 37 CFR §1.98(d), copies of cited documents noted with an asterisk are not enclosed because they were previously submitted in U.S. Patent Application No. / , which is relied on for an earlier effective filing date under 35 USC §120, and which included an Information Disclosure Statement that complies with 37 CFR §1.98(a) through (c).

_	А сору	of an Ir	ternational Preliminary Examination Report dated	_ for Application No.		
_	If any of the cited/submitted documents is in a foreign language, a concise explanation of relevance is provided pursuant to 37 C.F.R. §1.98(a)(3)(i). For foreign language documents cited in a search report by a foreign patent office, the requirement for a concise explanation of relevance is satisfied by the submission herewith of an English language version of the search report. MPEP §609A(3). If a written English-language translation of a non-English language document, or portion thereof, is within the possession, custody or control of, or is readily available to any individual designated in §1.56(c), a copy of the translation accompanies this statement, 37 C.F. §1.98(a)(3)(ii), and satisfies the requirement for a concise explanation of relevance, MPEP §609A(3).					
This statement should be considered because:						
	✓ 37 C.F.R. §1.97(b). This statement qualifies under 37 C.F.R. §1.97, subsection (b) became			ubsection (b) because:		
		(1)	It is being filed within three months of the filing date of an a continued prosecution application under § 1.53(d); OR	application other than		
		(2)	It is being filed within 3 months of entry of a national stage; OR			
	(3) It is being filed before the mailing date of the first Office Action on the merit OR		ction on the merits,			
		(4)	It is being filed before the mailing date of the first Office Ac a Request for Continued Examination under 37 C.F.R. §1.1			
	37 C.F.R. §1.97(e). Although it may not qualify under subsection (b), this statement qualifies under 37 C.F.R. §1.97, <u>subsection (c)</u> because:					
	<ol> <li>It is being filed before the mailing date of a FINAL Office Action, a Notice of Allowance, or an action that otherwise closes prosecution in the subject application whichever occurs first.</li> </ol>			he subject application,		
		_	AND (check at least one of the following,  (1) It is accompanied by a STATEMENT as set forth in  OR			
		_	(2) It is accompanied by the \$180 fee set forth in 37 C.I	F.R. §1.17(p).		
	37 C.F.R. §1.97(d). Although it may not qualify under subsection (b) or (c), this statemen qualifies under 37 C.F.R. §1.97, subsection (d) because:			) or (c), this statement		
	(1) It is being filed on or before payment of the Issue Fee; AND					
	(2) It is accompanied by a STATEMENT as set forth in 37 C.F.R. §1.97(e); AND			R. §1.97(e);		
	(3) It is accompanied by the \$180 fee set forth in 37 C.F.R. §1.17(p).		17(p).			

A copy of an International Search Report dated for Application No. .

PTA Statement under 37 C.F.R. §1.704(d). Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart

application and this communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of the *Information Disclosure Statement*.

- 37 C.F.R. §1.97(e)(1). THE UNDERSIGNED ATTORNEY HEREBY STATES THAT each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- 37 C.F.R. \$1.97(e)(2). THE UNDERSIGNED ATTORNEY HEREBY STATES THAT no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing this statement after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in \$1.56(c) more than three months prior to the filing of his statement.
- Fee Authorization. The Commissioner is hereby authorized to charge any deficiencies or credit any overpayment to Deposit Account No. 06-1325.

Respectfully submitted,

Reg. No. 57,253

FLIESLER MEYER LLP

Date: February 4, 2009 By: /Thomas K, Plunkett/
Thomas K, Plunkett

FLIESLER MEYER LLP 650 California Street, 14<sup>th</sup> Floor San Francisco, California 94108 Telephone (415) 362-3800 Customer No. 80548

U.S. Patent Application No. 10/788,802 Attorney Docket No.: ORACL-01338US2 tplunkett/oracl/1338us2/1338us2 ids.wpd